Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
Tweet Send to a Friend
Roth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.Ahead of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
